A5101670665- Nanoparticle-Based Drug Delivery
- Angiogenesis and VEGF in Cancer
- Drug Transport and Resistance Mechanisms
- Immunotherapy and Immune Responses
- RNA Interference and Gene Delivery
- Nanoplatforms for cancer theranostics
- Advanced Drug Delivery Systems
- Cancer, Hypoxia, and Metabolism
- Cell death mechanisms and regulation
- Pancreatic function and diabetes
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Proteoglycans and glycosaminoglycans research
- Glycosylation and Glycoproteins Research
- Extracellular vesicles in disease
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Research Studies
- Phagocytosis and Immune Regulation
- Immune Cell Function and Interaction
- Drug Solubulity and Delivery Systems
- Ferroptosis and cancer prognosis
- Immune cells in cancer
- Sinusitis and nasal conditions
- Genomics, phytochemicals, and oxidative stress
- Cancer-related Molecular Pathways
Kyung Hee University
2023-2025
Chonnam National University Hospital
2009-2023
Chonnam National University
2010-2023
Seoul National University
2014-2022
The current study sought to design an oral delivery system of pemetrexed (PMX), a multitargeted antifolate antimetabolite, by enhancing its intestinal membrane permeability.PMX was ionically complexed with permeation enhancer such as Nα-deoxycholyl-l-lysyl-methylester (DCK) and prepared amorphous solid dispersion mixing dispersants 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD) poloxamer 188 (P188), forming HP-beta-CD/PMX/DCK/P188; the complex incorporated into multiple water-in-oil-in-water...
Triple-negative breast cancer (TNBC) is characterized by its highly heterogeneous microenvironment and propensity for aggressive behavior, both of which represent, along with poor prognosis high incidence relapse, the main challenges curing disease. Although recent progress in targeted chemotherapy combinations has shown promising outcomes, conventional chemotherapeutic approaches have relied on exploiting expression certain molecules or proteins overexpressed cells as drug targets,...
Abstract Tumor heterogeneity is associated with the therapeutic failures of targeted therapies. To overcome such heterogeneity, a novel therapy proposed that could kill tumor populations diverse phenotypes by delivering nonselective cytotoxins to target‐positive cells as well surrounding via recurrent bystander killing effect. A representative prodrug prepared targets integrin αvβ3 and releases upon entering or caspase‐3. This allows αvβ3‐positive upregulate caspase‐3, which in turn,...
Controlled and site-specific regulation of growth factor signaling remains a major challenge for current antiangiogenic therapies, as these agents target normal vasculature well tumor vasculature. In this article, we identified the prion-like protein doppel potential therapeutic angiogenesis. We investigated interactions between VEGFR2 evaluated whether blocking doppel/VEGFR2 axis suppresses process discovered that endothelial cells (TECs), but not ECs, express doppel; tumors from patients...
The current study demonstrates the process of selecting an optimal structure for a caspase-3-cleavable doxorubicin prodrug that could be synthesized by simple chemistry in high yields. was intended to activate presence caspase-3, whose expression can exogenously regulated inducing apoptosis with radiation therapy at specific site interest. For this purpose, conjugated DEVD peptide via heterobifunctional linker. Since active form comprises linker besides doxorubicin, we tested several...
In this study, a system for oral delivery of etoposide (ETP) was designed to avoid the problems associated with low and variable bioavailability commercially available ETP emulsion comprised polyethylene glycol, glycerol, citric acid anhydrous. complexed low-molecular-weight methylcellulose (ETP/LMC) loaded into water-in-oil-in-water multiple nanoemulsion formulate an ETP/LMC-nanoemulsion (ELNE). To further enhance bioavailability, ionic complex formed by anionic lipid...
Here we report a novel combination of caspase-cleavable peptide-doxorubicin conjugate (MPD-1) with CD47-antagonizing nanocage therapeutics for the treatment microsatellite-stable (MSS) colorectal cancer (CRC). MPD-1 (i) upregulated markers immunogenic cell death (ICD) in tumor, and increased co-stimulatory on dendritic cells (DCs), (ii) enhanced CD8+ T infiltration antigen presenting (APC) activation, (iii) showed negligible off-target immune-related toxicity compared to free dox. Then, CD47...
Background: For maintenance therapy in type 2 diabetes, glucagon-like peptide-1 agonist (GLP-1A), which exhibits low cardiovascular risk and high efficacy, is a promising peptide therapeutic.However, developing an oral GLP-1A presents challenges due to the analog's poor cellular permeability gastrointestinal (GI) stability.Methods: To mitigate such limitations, nanoformulation of liraglutide (LG) was designed achieved by combining LG with bile acid derivatives using nanoprecipitation...
The rational combination of immunotherapy with standard chemotherapy shows synergistic clinical activities in cancer treatment. In the present study, an oral powder formulation pemetrexed (PMX) was developed to enhance intestinal membrane permeability and investigate its application metronomic immunotherapy.PMX ionically complexed a bile acid derivative (Nα-deoxycholyl-l-lysyl-methylester; DCK) as permeation enhancer mixed dispersing agents, such poloxamer 188 (P188) Labrasol, form amorphous...